Free Nurse Practitioner CE

This MedHive™ educational initiative focuses on empowering endocrinologists to deliver personalized, evidence-based care for patients with type 2 diabetes. Through interactive peer discussions and expert insights, participants will contribute their collective knowledge to explore strategies to optimize therapy selection, improve adherence, and achieve both glycemic and extra-glycemic goals aligned with the latest 2025 ADA Standards of Care.

In this online, self-learning activity:

Osteoporosis in aging men is a growing public health problem yet remains under-recognized in primary and specialty care. Population-based cohorts show that adults aged ≥80 years now account for most hip fractures, and in this age group men experience higher perioperative morbidity and mortality than women at comparable ages. Contemporary US trend analyses confirm a high and in some groups increasing prevalence of osteoporosis and low bone mass among adults ≥50 years, with substantial burden among older men. Health-economic models and actuarial reports estimate more than two million osteoporotic fractures annually in the United States, costing about $17 billion in 2005 and rising to an estimated $57 billion over the past two decades, with further growth expected by 2040; men already account for more than one-quarter of this burden. Prospective outcomes work from the ICUROS US study and Medicare claims analyses underscores prolonged quality-of-life loss and markedly higher all-cause costs after fragility fractures, especially hip and vertebral fractures in older adults, including men.

Expert faculty dive into the rapidly evolving world of BCMA-directed bispecific antibodies for multiple myeloma, exploring practical strategies to bring these cutting-edge therapies into everyday clinical care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Upon completion of this activity, learners will be able to:

• Implement routine OSA screening for patients with obesity and other OSA risk factors.
• Identify tools that can aid in screening patients for OSA.
• Initiate diagnostic workups for patients with suspected OSA.
• Evaluate results from OSA diagnostic studies.
• Implement multidisciplinary approaches to formulate tailored management strategies for OSA that account for patient preferences and new therapeutic options.

Discover how communities of practice are expanding access to bispecific antibodies, as faculty share practical guidance on starting these therapies in community settings and smoothly transitioning patients from academic centers to local care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

In this brief 15-minute activity, you will:

– Follow the case of a patient who presents with foot drop and no other medical conditions
– Choose optimal management approaches by answering nongraded questions within the activity (answers are collected for informational purposes only and used to assess the effectiveness of this educational activity)
– See how your answers compare with those of your peers
– View video clips providing expert insights

In this CME activity, discover the latest information on investigational factor XI/XIa inhibitors, including results from completed clinical trials and news about ongoing clinical trials, to explore their potential role in managing stroke risk in patients with atrial fibrillation (AF).

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Empowering the Care Team: Practical Strategies for Implementing BCMA Therapies in Relapsed Refractory Multiple Myeloma

Through interactive cases and expert-led discussions, our ECHO® sessions and Community of Practice calls help community oncology teams:

• Characterize the safety and efficacy of BCMA-directed bsAbs for the treatment of MM
• Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
• Establish and follow workflows and lines of communication for monitoring and managing BCMA bsAb treatment-related adverse events
• Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed bsAbs

In this online, self-learning activity:

Neonatal respiratory distress syndrome (nRDS) remains a leading cause of respiratory failure and morbidity among preterm infants worldwide, despite major advances in antenatal steroids, continuous positive airway pressure (CPAP), and surfactant therapy. Contemporary guidelines emphasize early noninvasive respiratory support from birth, selective surfactant rescue once CPAP begins to fail, and structured, protocolized care across gestational age strata. Yet practice-pattern studies across high- and middle-income settings show wide variation in initial respiratory support, surfactant thresholds, and use of minimally invasive techniques, with extremely preterm and late preterm infants often receiving care that diverges from guideline-concordant pathways. These inconsistencies increase cumulative ventilator exposure and risk of bronchopulmonary dysplasia (BPD) and other complications, underscoring a persistent implementation gap between best evidence and routine NICU care.

In this online, self-learning activity:

Asthma remains a highly prevalent chronic respiratory disease, affecting more than 26 million people in the United States, including over 4.5 million children, with several thousand deaths and substantial emergency department and inpatient utilization each year despite effective preventives. Persistent symptoms, recurrent exacerbations, and preventable hospitalizations indicate gaps in risk stratification and in the consistent application of guideline-based care, even with comprehensive frameworks such as the Global Initiative for Asthma (GINA) strategy. Many severe attacks still occur, requiring parenteral bronchodilators, systemic corticosteroids, magnesium sulfate, oxygen, and respiratory-support devices, underscoring missed opportunities to optimize maintenance regimens and device use upstream.

Type 2 diabetes (T2D) rarely travels alone. Most patients carry overlapping cardiovascular, renal, and metabolic (CKM) risk, and this convergence is now central to how T2D should be managed, not a comorbidity footnote. Despite clear guideline recommendations, GLP-1 RAs and dual GIP/GLP-1 RAs with proven cardiovascular and renal benefit remain underused among patients who stand to gain the most. Patient complexity, an expanding evidence base for outcomes, and persistent clinical inertia all contribute to this gap.

Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.

Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other respiratory diseases such as COPD and asthma. Persistent airway inflammation, chronic infection, and mucociliary dysfunction drive disease progression, leading to significant morbidity and healthcare burden. As the clinical burden of bronchiectasis becomes increasingly recognized, there is an urgent need to better understand the underlying mechanisms of neutrophilic inflammation, alongside efforts to improve early diagnosis and explore current and emerging treatment options that target this vicious cycle.

In this activity, a panel of leading pulmonologists tackle the evolving challenges and emerging opportunities in bronchiectasis management. From diagnostic workup to airway clearance and exacerbation control, the discussion will blend expert insight with real-world clinical scenarios and patient perspectives.
Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.

This webcast focuses on the role of wearable devices in the timely identification of atrial fibrillation (AF) and the evolving evidence around the rationale for and efficacy/safety of early rhythm control strategies, including guideline recommendations and expert insights on the use of antiarrhythmic drugs (AADs) and catheter ablation. It also incorporates an AI-powered patient simulator as a method by which participants can practice how they engage patients in shared decision-making discussions regarding rhythm control strategies

Hear from a panel of clinicians from community practices about their experiences, including the challenges and successes, with integrating B-cell maturation antigen (BCMA)-directed bispecific antibodies into their practices. Explore patient management strategies for bispecific antibodies, from starting treatment at a community center to providing long-term care after treatment initiation at either a community or tertiary center.

This CME activity reviews the efficacy and safety of available B-cell maturation antigen (BCMA)-directed bispecific antibodies for multiple myeloma and explores the latest clinical data on their use in earlier lines of therapy and in emerging combination regimens.

This CME activity reviews various barriers to accessing B-cell maturation antigen (BCMA)-directed therapies that patients with multiple myeloma may experience. The impact of these barriers on health outcomes is discussed, along with strategies and policy solutions to help overcome them.

This CME activity explores the latest clinical data and provides guidance on when to consider treatment with available B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T-cell therapy, or antibody-drug conjugate (ADC) therapy for patients with relapsed/refractory multiple myeloma (RRMM) based on patient-, disease-, and treatment-related factors.

In this MedX activity, Michael Blaha, MD, explores the evolving landscape of low-density lipoprotein cholesterol (LDL-C) management in patients with atherosclerotic cardiovascular disease (ASCVD), with a focus on the current role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how emerging novel PCSK9 inhibitor formulations may be integrated into clinical practice as they become available.